Compare · AZN vs MPLT
AZN vs MPLT
Side-by-side comparison of AstraZeneca PLC (AZN) and MapLight Therapeutics Inc. (MPLT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AZN and MPLT operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- AZN is the larger of the two at $255.13B, about 156.3x MPLT ($1.63B).
- Over the past year, AZN is down 10.2% and MPLT is up 104.9% - MPLT leads by 115.1 points.
- AZN has been more active in the news (12 items in the past 4 weeks vs 11 for MPLT).
- AZN has more recent analyst coverage (25 ratings vs 12 for MPLT).
- Company
- AstraZeneca PLC
- MapLight Therapeutics Inc.
- Price
- $169.09+2.80%
- $37.43+3.81%
- Market cap
- $255.13B
- $1.63B
- 1M return
- -3.33%
- +29.85%
- 1Y return
- -10.20%
- +104.87%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2026
- 2025
- News (4w)
- 12
- 11
- Recent ratings
- 25
- 12
AstraZeneca PLC
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; and Proteros biostructures GmbH to discover and develop novel small molecules for the treatment of various types of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Latest AZN
- SEC Form 6-K filed by AstraZeneca PLC
- AstraZeneca downgraded by HSBC Securities
- SEC Form 6-K filed by AstraZeneca PLC
- Officer Sharma Mani was granted 2 units of Ordinary Shares, increasing direct ownership by 0.01% to 19,265 units (SEC Form 4)
- The Quantum Sector Hits an Inflection Point: Federal Money, Real Milestones, and a Security Race Running in Parallel
- Abbisko Therapeutics and AstraZeneca Enter a Strategic Collaboration to Conduct the Clinical Trial of Lumipodlin (ABSK043), a First-in-Class Oral PD-L1 Inhibitor, in Combination with TAGRISSO® for NSCLC
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 11-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
Latest MPLT
- BMO Capital Markets initiated coverage on MapLight Therapeutics with a new price target
- Chief Discovery Officer Kreitzer Anatol sold $1,345,894 worth of Voting Common Stock (36,284 units at $37.09) as part of a pre-agreed trading plan, decreasing direct ownership by 17% to 174,906 units (SEC Form 4) to cover withholding tax
- CAO and Interim CFO Gillis Jonathan sold $1,372,668 worth of Voting Common Stock (36,979 units at $37.12) as part of a pre-agreed trading plan, decreasing direct ownership by 20% to 144,240 units (SEC Form 4) to satisfy tax liability
- Chief Executive Officer Kroeger Christopher A. sold $5,443,722 worth of Voting Common Stock (147,639 units at $36.87), decreasing direct ownership by 11% to 1,246,455 units (SEC Form 4) to satisfy withholding obligation
- Chief Scientific Officer Lillie James Woodruff sold $673,636 worth of Voting Common Stock (18,267 units at $36.88), decreasing direct ownership by 8% to 224,462 units (SEC Form 4) to satisfy withholding obligation
- General Counsel Hanson Kristopher sold $607,870 worth of Voting Common Stock (16,508 units at $36.82), decreasing direct ownership by 10% to 145,823 units (SEC Form 4) to cover taxes
- Chief Medical Officer Foff Erin Pennock sold $1,734,490 worth of Voting Common Stock (47,158 units at $36.78) as part of a pre-agreed trading plan, decreasing direct ownership by 14% to 298,901 units (SEC Form 4) (withholding obligation)
- SEC Form 144 filed by MapLight Therapeutics Inc.
- SEC Form 144 filed by MapLight Therapeutics Inc.
- SEC Form 144 filed by MapLight Therapeutics Inc.